Trial intelligence / Profile preview

Phase 2 study of simeprevir + daclatasvir + ribavirin in recurrent hepatitis C genotype 1b after liver transplantation

2013-002726-23Phase 2Completed

Sponsor

Janssen Pharmaceutical

Start

Oct 2013

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1